Press Releases

Titan Pharmaceuticals Schedules Conference Call to Review Fourth Quarter and Full Year 2012 Financial Results

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/11/13 -- Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 8 a.m. PT / 11 a.m. ET on Monday, March 18, 2013. Titan will provide the Company's financial results as of December 31, 2012. The call will be hosted by Sunil Bhonsle, president, Katherine Glassman-Beebe, Ph.D., executive vice president and chief development officer, Brian Crowley, vice president of finance and Marc Rubin, M.D., executive chairman.

Highlights of the fourth quarter financial results will be included in a press release to be issued prior to the call.

The live webcast of the call may be accessed by visiting the Titan website at The call can also be accessed by dialing 888-539-3678 Participant code: 7140768 five minutes prior to the start time. A replay of the call will be available on the Company website approximately two hours after completion of the call and will be archived for two weeks.

About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developing proprietary therapeutics for the treatment of serious medical disorders. Titan's principal asset is Probuphine®, a buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine, which is undergoing FDA review with a PDUFA target action date of April 30, 2013, is the first product to utilize ProNeura™, the company's novel, proprietary, long-term drug delivery technology. The ProNeura technology has the potential to be used in developing products for the treatment of other chronic conditions, such as Parkinson's disease, where maintaining stable, around-the-clock blood levels of a drug could potentially benefit the patient and improve medical outcomes. For more information, please visit the Company's website at

The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.

For Investors:
Titan Pharmaceuticals, Inc.
Sunil Bhonsle

For Media:
Pure Communications
Dan Budwick

Source: Titan Pharmaceuticals, Inc.